Demographic, clinical, genetic, and outcome features of MRC ALL97/99 and UKALL2003 patients with BCP-ALL and intermediate-risk cytogenetics stratified according to CNA risk profile
| Variable/category . | IR cytogenetic patients . | |||||
|---|---|---|---|---|---|---|
| ALL97/99 . | UKALL2003 . | |||||
| CNA-GR profile group A, n (%) . | CNA-IR/PR profile group B, n (%) . | P . | CNA-GR profile group A, n (%) . | CNA-IR/PR profile group B, n (%) . | P . | |
| Total number of patients | 110 (41) | 157 (59) | — | 108 (44) | 138 (56) | — |
| Sex | ||||||
| Female | 55 (50) | 66 (42) | .2 | 45 (41) | 60 (44) | .7 |
| Male | 55 (50) | 91 (58) | 63 (59) | 78 (56) | ||
| Age (y) | ||||||
| 1-9 | 78 (71) | 102 (65) | .5 | 71 (66) | 78 (56) | .3 |
| 10-14 | 26 (23) | 47 (30) | 21 (19) | 36 (26) | ||
| ≥15 | 6 (5) | 8 (5) | 16 (15) | 24 (18) | ||
| WCC | ||||||
| <50 × 109/L | 95 (86) | 101 (64) | <.001 | 92 (85) | 107 (77) | .1 |
| >50 × 109/L | 15 (14) | 56 (36) | 16 (15) | 31 (23) | ||
| NCI risk group* | ||||||
| Standard | 67 (61) | 60 (38) | <.001 | 57 (53) | 56 (40) | .05 |
| High | 43 (39) | 97 (62) | 51 (47) | 82 (60) | ||
| MRD† | ||||||
| LR | — | — | — | 36 (33) | 55 (39) | .8 |
| HR | — | — | 43 (39) | 59 (43) | ||
| IR | — | — | 29 (28) | 24 (17) | ||
| Complete remission | ||||||
| No | 0 (0) | 5 (3) | .08 | 0 (0) | 0 (0) | — |
| Yes | 110 (100) | 152 (97) | 108 (100) | 138 (100) | ||
| Event | ||||||
| No | 85 (77) | 91 (58) | — | 104 (96) | 114 (82) | — |
| Yes | 25 (23) | 66 (42) | 4 (4) | 24 (18) | ||
| Relapse | ||||||
| No | 91 (83) | 97 (64) | — | 105 (97) | 119 (86) | — |
| Yes | 19 (17) | 55 (36) | 3 (3) | 19 (14) | ||
| Dead | ||||||
| No | 92 (84) | 107 (68) | — | 106 (98) | 120 (87) | — |
| Yes | 18 (16) | 50 (32) | 2 (2) | 18 (13) | ||
| Variable/category . | IR cytogenetic patients . | |||||
|---|---|---|---|---|---|---|
| ALL97/99 . | UKALL2003 . | |||||
| CNA-GR profile group A, n (%) . | CNA-IR/PR profile group B, n (%) . | P . | CNA-GR profile group A, n (%) . | CNA-IR/PR profile group B, n (%) . | P . | |
| Total number of patients | 110 (41) | 157 (59) | — | 108 (44) | 138 (56) | — |
| Sex | ||||||
| Female | 55 (50) | 66 (42) | .2 | 45 (41) | 60 (44) | .7 |
| Male | 55 (50) | 91 (58) | 63 (59) | 78 (56) | ||
| Age (y) | ||||||
| 1-9 | 78 (71) | 102 (65) | .5 | 71 (66) | 78 (56) | .3 |
| 10-14 | 26 (23) | 47 (30) | 21 (19) | 36 (26) | ||
| ≥15 | 6 (5) | 8 (5) | 16 (15) | 24 (18) | ||
| WCC | ||||||
| <50 × 109/L | 95 (86) | 101 (64) | <.001 | 92 (85) | 107 (77) | .1 |
| >50 × 109/L | 15 (14) | 56 (36) | 16 (15) | 31 (23) | ||
| NCI risk group* | ||||||
| Standard | 67 (61) | 60 (38) | <.001 | 57 (53) | 56 (40) | .05 |
| High | 43 (39) | 97 (62) | 51 (47) | 82 (60) | ||
| MRD† | ||||||
| LR | — | — | — | 36 (33) | 55 (39) | .8 |
| HR | — | — | 43 (39) | 59 (43) | ||
| IR | — | — | 29 (28) | 24 (17) | ||
| Complete remission | ||||||
| No | 0 (0) | 5 (3) | .08 | 0 (0) | 0 (0) | — |
| Yes | 110 (100) | 152 (97) | 108 (100) | 138 (100) | ||
| Event | ||||||
| No | 85 (77) | 91 (58) | — | 104 (96) | 114 (82) | — |
| Yes | 25 (23) | 66 (42) | 4 (4) | 24 (18) | ||
| Relapse | ||||||
| No | 91 (83) | 97 (64) | — | 105 (97) | 119 (86) | — |
| Yes | 19 (17) | 55 (36) | 3 (3) | 19 (14) | ||
| Dead | ||||||
| No | 92 (84) | 107 (68) | — | 106 (98) | 120 (87) | — |
| Yes | 18 (16) | 50 (32) | 2 (2) | 18 (13) | ||
NCI standard risk includes patients who at diagnosis were <10 years old and had a WCC <50 × 109/L. NCI HR includes all other cases.
MRD was evaluated by real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements as defined by the European MRD Study Group. Patients were classified by MRD at day 29 (end of induction) as HR (>0.01%), LR (<0.01%), or indeterminate (no sample, test failed). Patients treated on ALL97/99 were not evaluated by MRD.